Daptomycin-Oxacillin Combinations in Treatment of Experimental Endocarditis Caused by Daptomycin-Nonsusceptible Strains of Methicillin-Resistant Staphylococcus aureus with Evolving Oxacillin Susceptibility (the “Seesaw Effect”)
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
In vivo development of daptomycin resistance (DAP r ) among Staphylococcus aureus strains, especially methicillin-resistant S. aureus (MRSA) strains, in conjunction with clinical treatment failures, has emerged as a major problem. This has raised the question of DAP-based combination regimens to enhance efficacy against such strains. We studied five recent DAP-susceptible (DAP s )/DAP r clinical MRSA strain pairs obtained from patients who failed DAP monotherapy regimens, as well as one DAP s /DAP r MRSA strain pair in which the resistant strain was generated by in vitro passage in DAP. Of note, we identified a DAP-oxacillin (OX) “seesaw” phenomenon in vitro in which development of DAP r was accompanied by a concomitant fall in OX resistance, as demonstrated by 3- to 4-fold decreases in the OX MIC, a susceptibility shift by population analyses, and enhanced early killing by OX in time-kill assays. In addition, the combination of DAP and OX exerted modest improvement in in vitro bactericidal effects. Using an experimental model of infective endocarditis and two DAP s /DAP r strain pairs, we demonstrated that (i) OX monotherapy was ineffective at clearing DAP r strains from any target tissue in this model (heart valve, kidneys, or spleen) and (ii) DAP-OX combination therapy was highly effective in DAP r strain clearances from these organs. The mechanism(s) of the seesaw effect remains to be defined but does not appear to involve excision of the staphylococcal cassette chromosome mec (SCC mec ) that carries mecA .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
LaPlante, K. L., & Rybak, M. J. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4665-4672.2004 · Cited by 284
Donnio, P.-Y., Oliveira, D. C., Faria, N. A., Wilhelm, N., Le Coustumier, A., & de Lencastre, H. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.8.4191-4193.2005 · Cited by 82 · cited 1×
“This loss of methicillin resistance has most often been due to excision of the staphylococcal cassette chromosome mec element (SCCmec) that carries mecA, the gene encoding penicillin-binding protein 2a (PBP2a), which is responsible for the MRSA phenotype (11, 12, 37).”
BackgroundChambers, H. F., Basuino, L., Diep, B. A., Steenbergen, J., Zhang, S., Tattevin, P., & Alder, J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01307-08 · Cited by 42
Cited by
Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L., & Fowler, V. G. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00134-14 · Cited by 5,192
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Self-citationDhand, A., Bayer, A. S., Pogliano, J., Yang, S.-J., Bolaris, M., Nizet, V., Wang, G., & Sakoulas, G. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir340 · Cited by 252
“a mecA-independent manner [7].”
BackgroundSelf-citationSakoulas, G., Bayer, A. S., Pogliano, J., Tsuji, B. T., Yang, S.-J., Mishra, N. N., Nizet, V., Yeaman, M. R., & Moise, P. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05551-11 · Cited by 176
Self-citationMehta, S., Singh, C., Plata, K. B., Chanda, P. K., Paul, A., Riosa, S., Rosato, R. R., & Rosato, A. E. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01525-12 · Cited by 142
Metadata
- Authors
- Yang, S.-J., Xiong, Y. Q., Boyle-Vavra, S., Daum, R., Jones, T., & Bayer, A. S.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2010-08
- Volume
- 54
- Issue
- 8
- Pages
- 3161-3169
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2132514720
- Cited by
- 130
- References
- 3
- FWCI
- 7.49
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.